<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Enteric (typhoid and paratyphoid) fever: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Enteric (typhoid and paratyphoid) fever: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Enteric (typhoid and paratyphoid) fever: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason Andrews, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob John, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richelle C Charles, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Enteric fever is characterized by severe systemic illness with fever and abdominal pain [<a href="#rid1">1</a>]. The organism classically responsible for the enteric fever syndrome is <em>Salmonella</em> <em>enterica</em> serotype Typhi (formerly <em>S</em>. <em>typhi</em>). Other <em>Salmonella</em> serotypes, particularly <em>S. enterica</em> serotypes Paratyphi A, B, or C, can cause a similar syndrome; however, it is usually not clinically useful or possible to reliably predict the causative organism based on clinical findings [<a href="#rid2">2</a>]. The term "enteric fever" is a collective term that refers to both typhoid and paratyphoid fever, and "typhoid" and "enteric fever" are often used interchangeably.</p><p>The treatment and prevention of enteric fever will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of enteric fever are discussed separately. (See  <a class="medical medical_review" href="/d/html/2703.html" rel="external">"Pathogenesis of enteric (typhoid and paratyphoid) fever"</a> and  <a class="medical medical_review" href="/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4291984372"><span class="h1">ANTIMICROBIAL RESISTANCE</span><span class="headingEndMark"> — </span>Treatment of enteric fever has been complicated by the development and rapid global spread of typhoidal organisms resistant to <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>. Additionally, development of increasing resistance to fluoroquinolones and cephalosporins is a growing challenge.</p><p class="headingAnchor" id="H4"><span class="h2">Fluoroquinolone resistance</span><span class="headingEndMark"> — </span>Historically, resistance to the early generation quinolone nalidixic acid served as an important marker for decreased susceptibility to fluoroquinolones. However, because of the emergence of newer mechanisms of fluoroquinolone resistance, some isolates may appear to be sensitive to nalidixic acid but still have decreased sensitivity to clinically important fluoroquinolones, calling into question the reliability of using nalidixic acid resistance as a marker of fluoroquinolone resistance. As a result, both the Clinical and Laboratory Standards Institute (CLSI) in the United States and European Committee on Antimicrobial Susceptibility Testing have specific fluoroquinolone breakpoints for <em>Salmonella</em> isolates [<a href="#rid3">3-5</a>]. </p><p>CLSI guidelines consider a <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> MIC ≤0.06 mcg/mL and <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> MIC ≤0.12 mcg/mL as susceptible. Typhoidal <em>Salmonella </em>strains with MICs above these thresholds may be associated with clinical failure or delayed response to treatment with fluoroquinolones.</p><p>In many parts of South Asia, over 80 percent of <em>S. </em>Typhi isolated among clinical cases are nonsusceptible to fluoroquinolones [<a href="#rid6">6</a>]. A randomized trial in Nepal comparing <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> with <a class="drug drug_general" data-topicid="8928" href="/d/drug information/8928.html" rel="external">gatifloxacin</a>, a fluoroquinolone that had proven highly successful in the country just several years prior, had to be terminated early due to high rates of treatment failure in the gatifloxacin arm, which was associated with fluoroquinolone nonsusceptibility. In contrast, fluoroquinolone-nonsusceptibility appears less common in other parts of the world. In one multi-country study in Africa, fluoroquinolone nonsusceptibility was only documented in one (Kenya) [<a href="#rid7">7</a>] of six countries performing surveillance. More recently, fluoroquinolone resistant isolates have been reported in Nigeria [<a href="#rid8">8</a>]. Throughout Africa, rates of fluoroquinolone nonsusceptibility in typhoidal <em>Salmonella </em>remain low but are rising [<a href="#rid9">9</a>].</p><p>Increasing rates of full resistance to fluoroquinolones have also been reported; in some cases, these resistant isolates have been classified as a subclass of the multidrug resistant (MDR) H58 typhoid strain that had widely disseminated throughout Asia and some African countries [<a href="#rid10">10</a>]. A compilation of studies showed rates of fully quinolone-resistant organisms ranged from 0 to 13 percent, with cases reported from India, Korea, and Nepal [<a href="#rid11">11</a>]. In a systematic review of studies from Nepal, the pooled rates of <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> resistance increased in both <em>S. </em>Typhi and <em>S. </em>Paratyphi A, from 1.6 and 3.9 percent in 1998 to 2002 to 10.6 and 14.3 percent in 2008 to 2011 [<a href="#rid12">12</a>]. Cases of high-level resistance to ciprofloxacin, often conferred by strains containing multiple mutations in the quinolone resistance-determining region have also been reported throughout South Asia in both <em>S. </em>Paratyphi and <em>S. </em>Typhi (MICs ≥8 mcg/mL) [<a href="#rid13">13-15</a>]. Given the rapid global spread of prior drug-resistant <em>Salmonella </em>strains from South Asia, there is concern that these highly resistant strains will soon appear in other parts of the world.</p><p class="headingAnchor" id="H4174275090"><span class="h2">Resistance to other agents</span><span class="headingEndMark"> — </span>Most <em>S. </em>Typhi and <em>S. </em>Paratyphi isolates remain susceptible to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, although resistant isolates have been reported. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ceftriaxone</strong><strong> resistance</strong> − In particular, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> resistance is increasing, with reports of patients with extended-spectrum beta-lactamase-producing <em>S. </em>Typhi and <em>S. </em>Paratyphi infections [<a href="#rid16">16-18</a>]. A cluster of ceftriaxone-resistant <em>S.</em> Typhi infections has been linked to travel to Iraq [<a href="#rid19">19</a>]. Multiple reports of ceftriaxone-resistant infections mediated by the acquisition of drug-resistant plasmids, such as IncX3, have been reported from India. These strains remain susceptible to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, and carbapenems [<a href="#rid20">20-22</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azithromycin</strong><strong> resistance</strong> − Clearly defined MIC breakpoints for <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> susceptibility have not been established, but data suggest that <em>S. Typh</em>i isolates with an MIC ≤16 mcg/mL generally respond well to azithromycin (which is concentrated intracellularly at levels 50 to 100 times greater than serum levels) and can be considered susceptible [<a href="#rid23">23</a>]. A 15 mcg disk susceptibility zone size of ≥13 mm appears consistent with an azithromycin MIC ≤16 mcg/mL (99.7 percent sensitive). </p><p></p><p class="bulletIndent1">The first report of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> resistance (MIC by E-test 64 mcg/mL) <em>in S. Para</em>typhi A resulting in treatment failure was reported in a traveler returning from Pakistan to Great Britain [<a href="#rid24">24</a>]. The patient was successfully treated with a two-week course of intravenous <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, 2 g daily. A growing number of azithromycin-resista<em>nt S. Typhi</em> a<em>nd S. Para</em>typhi A isolates have also been reported from South Asia, although this phenotype has not been seen in ceftriaxone-resistant organisms [<a href="#rid25">25-27</a>]. It appears to be mediated by R717Q/L mutations in t<em>he acrB gen</em>e [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H1170984158"><span class="h2">Multidrug resistance</span><span class="headingEndMark"> — </span>MDR strains (ie, those resistant to <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>) are prevalent worldwide, though they have been in decline as other antibiotics have been more widely used for treatment of enteric fever. </p><p>MDR strains of <em>S. </em>Typhi and <em>S. </em>Paratyphi have caused numerous outbreaks in endemic regions, including South and Southeast Asia, China, and Africa [<a href="#rid29">29-31</a>]. Because of this, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> fell out of favor as first-line agents for treatment of enteric fever.</p><p>Prevalence of MDR strains varies, throughout Africa, the Middle East, and Central Asia, from 10 to 80 percent, depending on the country [<a href="#rid32">32-35</a>]. Genome sequencing and analysis of international isolates has identified a predominant MDR <em>S. </em>Typhi strain, H58, that has disseminated throughout Asia and Africa, displacing more susceptible strains and driving ongoing MDR epidemics [<a href="#rid36">36</a>]. As of 2018, approximately 75 percent of strains from Africa remain MDR, without significant change over the past 15 years [<a href="#rid9">9</a>].</p><p>However, some locations have reported a decrease in the prevalence of MDR strains. As an example, in a surveillance study from Kolkata, India conducted from 2009 to 2013, 18 percent of <em>S. </em>Typhi and no <em>S. </em>Paratyphi isolates were MDR [<a href="#rid37">37</a>]. A surveillance study of isolates collected across India between 2017 and 2020 demonstrated continued declining numbers, with 2 percent of<em> S</em>. Typhi and no <em>S</em>. Paratyphi A isolates that were MDR [<a href="#rid38">38</a>]. These patterns of resistance are reflected in travelers returning to nonendemic regions. In an analysis of over 1000 isolates submitted to the United States Centers for Disease Control and Prevention between 2008 and 2012, most of which were from infections acquired in South Asia, 13 percent of <em>S. </em>Typhi and no <em>S. </em>Paratyphi isolates were MDR strains [<a href="#rid39">39</a>]. In a subsequent Surveillance of Enteric Fever in Asia Project study, a minority of strains from India, Nepal, and Bangladesh were MDR, while the majority of strains from Pakistan continued to show multidrug resistance [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H540177460"><span class="h2">Extensively drug-resistant typhoid</span><span class="headingEndMark"> — </span>Extensively drug-resistant (XDR) strains (ie, those resistant to five antibiotics: <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, fluoroquinolones, and third-generation cephalosporins) has been described as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In 2016, a large outbreak of typhoid fever in Pakistan was caused by a strain resistant to <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, fluoroquinolones, and third-generation cephalosporins [<a href="#rid40">40,41</a>]. By the end of 2018, more than 5000 cases of this XDR <em>S.</em> Typhi strain were reported, with imported cases in the United Kingdom and the United States [<a href="#rid42">42-44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2020, several XDR typhoid cases in individuals with no prior international travel were reported in the United States, suggesting local transmission [<a href="#rid45">45</a>]. The strain remains susceptible to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and carbapenems, which are the main treatment options. (See <a class="local">'Empiric therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">ANTIMICROBIAL THERAPY</span><span class="headingEndMark"> — </span>Enteric fever is usually treated with a single antibacterial drug. Antibiotic selection depends upon the severity of illness, local resistance patterns, whether oral medications are feasible, the clinical setting, and available resources. The optimal choice of drug and duration of therapy are uncertain [<a href="#rid46">46-48</a>]. The main options are fluoroquinolones, third-generation cephalosporins, and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>. Carbapenems are reserved for suspected infection with extensively drug-resistant (XDR) strains. In some circumstances, older agents such as <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> may be appropriate, but these drugs are generally not used widely because of the prevalence of resistance. Oral chloramphenicol is no longer available in the United States but is still used in other parts of the world. </p><p class="headingAnchor" id="H959998367"><span class="h2">Empiric therapy</span><span class="headingEndMark"> — </span>When treating presumptively for enteric fever or before results of susceptibility testing are available, appropriate options for empiric therapy depend, in part, on the severity of disease and the risk of infection with an antibiotic-resistant isolate. </p><p class="headingAnchor" id="H1671911949"><span class="h3">Severe or complicated disease</span><span class="headingEndMark"> — </span>For patients who have severe disease (eg, systemic toxicity, depressed consciousness, prolonged fever, organ system dysfunction, or other feature that prompts hospitalization), initial therapy with a parenteral agent is appropriate. The geographic region where infection was likely acquired helps inform the choice of parenteral agent because of the risk of resistance in certain locations: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection acquired outside Pakistan</strong> <strong>or Iraq</strong> – For most patients with severe or complicated enteric fever without recent travel to Pakistan or Iraq, we suggest empiric therapy with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>. If ceftriaxone is not available, <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> is a reasonable alternative. Although some studies have demonstrated slower time to defervescence with cephalosporins (compared with fluoroquinolones), resistance to the third-generation cephalosporins is uncommon in most locations, and so ceftriaxone is likely to be an effective empiric agent in individuals without a history of travel to Pakistan or Iraq [<a href="#rid29">29</a>]. However, if there is suspicion for ceftriaxone resistance, a carbapenem can be used while awaiting susceptibility testing [<a href="#rid45">45</a>] (see <a class="local">'Extensively drug-resistant typhoid'</a> above). <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">Aztreonam</a> has been effective in small trials and can be used for individuals who cannot take cephalosporins because of allergy [<a href="#rid49">49,50</a>]. In situations where the risk of decreased susceptibility to fluoroquinolones is low (eg, disease not acquired from South Asia or Iraq), a parenteral fluoroquinolone is also an appropriate alternative. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection acquired in Pakistan or Iraq</strong> – For patients with severe or complicated enteric fever acquired in Pakistan or Iraq (eg, following recent travel to those countries), we suggest empiric therapy with a carbapenem (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>). This is because of the presence of XDR <em>S</em>. Typhi in these regions. (See <a class="local">'Extensively drug-resistant typhoid'</a> above.)</p><p></p><p>Antibiotic doses and durations are listed in the table  (<a class="graphic graphic_table graphicRef109995" href="/d/graphic/109995.html" rel="external">table 1</a>). Once symptoms improve, the patient can be transitioned to an oral agent, selected based on results of susceptibility testing, if available. Oral options and data evaluating the efficacy of antibiotic options for enteric fever are discussed elsewhere. (See <a class="local">'Directed therapy'</a> below.)</p><p>Adjunctive corticosteroid is an additional consideration for patients with severe enteric fever. (See <a class="local">'Adjunctive corticosteroids for severe infection'</a> below.)</p><p class="headingAnchor" id="H1961451367"><span class="h3">Uncomplicated disease</span><span class="headingEndMark"> — </span>Patients with uncomplicated disease have no evidence of systemic toxicity and can tolerate oral therapy. Appropriate options for empiric therapy in such patients depend on the risk of infection with an antibiotic-resistant isolate, which differs based on the geographical area where infection was acquired. (See <a class="local">'Fluoroquinolone resistance'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Fluoroquinolones (<a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a>) are the drugs of choice for empiric therapy when infection is expected to be fluoroquinolone susceptible. This includes infection acquired in most areas of sub-Saharan Africa (except for Kenya and Nigeria). However, since fluoroquinolone resistance has emerged quickly in some areas, susceptibility testing and continued surveillance of local resistance rates is recommended to guide empiric treatment. Although fluoroquinolones are not recommended for routine use in children in the United States because of arthropathy and cartilage toxicity in exposed immature animals [<a href="#rid51">51,52</a>], clinical studies have not demonstrated sustained injury to developing bones or joints in children treated with available fluoroquinolones [<a href="#rid53">53,54</a>]. Thus, fluoroquinolone use in children is acceptable for severe infection, such as enteric fever, when alternatives are not available or appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, for empiric oral therapy of patients with infections acquired in South Asia or other areas with a high risk of reduced susceptibility to fluoroquinolones (eg, nalidixic acid resistance), we suggest <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, which achieves excellent intracellular concentrations and has established efficacy. Azithromycin is also expected to have activity against XDR isolates acquired in Pakistan. Increasing numbers of azithromycin-resistant <em>S. </em>Typhi have been reported from South Asia, particularly Bangladesh, so susceptibility testing should be performed. (See <a class="local">'Fluoroquinolone resistance'</a> above and <a class="local">'Extensively drug-resistant typhoid'</a> above.)</p><p></p><p>Infection with an isolate with reduced susceptibility to fluoroquinolones (see <a class="local">'Fluoroquinolone resistance'</a> above) is associated with longer time to defervescence and higher rates of treatment failure with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a>, and <a class="drug drug_general" data-topicid="8928" href="/d/drug information/8928.html" rel="external">gatifloxacin</a> [<a href="#rid46">46,55-58</a>]. Over a period of 10 years, fluoroquinolone effectiveness markedly declined in this setting as resistance emerged; at the same time, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> remained effective and minimum inhibitory concentrations (MICs) were low and declining [<a href="#rid59">59</a>]. Resistance to azithromycin remains rare. </p><p>However, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> may be costly or unavailable in certain parts of the world, and parenteral therapy may not be necessary for many uncomplicated infections. In such cases, <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> is another alternative, but it has some drawbacks (see <a class="local">'Fluoroquinolone-nonsusceptible infection'</a> below). If multidrug resistance is not prevalent, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> (if available) are potential options (see <a class="local">'Multidrug resistance'</a> above). In resource-limited settings, options may be further constrained by cost and availability. </p><p>Antibiotic doses and durations are listed in the table  (<a class="graphic graphic_table graphicRef109995" href="/d/graphic/109995.html" rel="external">table 1</a>). If susceptibility testing demonstrates that an empirically chosen agent is active and the patient has improved, that agent can be continued as directed therapy. Data evaluating the efficacy of antibiotic options for enteric fever are discussed elsewhere. (See <a class="local">'Directed therapy'</a> below.)</p><p class="headingAnchor" id="H2150544001"><span class="h2">Directed therapy</span><span class="headingEndMark"> — </span>Ideally, definitive antimicrobial therapy for enteric fever should be based on results of susceptibility testing. <em>S. </em>Typhi and <em>S. </em>Paratyphi isolates should be directly tested for <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> sensitivity utilizing the breakpoints as described above [<a href="#rid3">3,60,61</a>]. However, such testing may be technically challenging, especially in resource-limited settings. Moreover, the diagnosis of enteric fever is often presumptive, without isolation of an organism. In cases in which susceptibility testing cannot be performed, options depend on the likelihood of antimicrobial resistance (see <a class="local">'Empiric therapy'</a> above). Infectious disease consultation is warranted for such cases if clinicians are not familiar with enteric fever and its treatment.</p><p>There are no trials demonstrating that combination antimicrobial therapy is superior to monotherapy for enteric fever. In a study of 37 individuals with nalidixic acid-resistant <em>S. </em>Paratyphi A bacteremia who were identified as part of an outbreak among Israeli travelers returning from Nepal, all patients improved without complications, but time to defervescence was shorter among those who were treated with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> compared with ceftriaxone alone [<a href="#rid62">62</a>]. Given the small size and observational nature of the study and the finding that all patients were infected by a single strain, additional study is needed to determine if there is any benefit of using two drugs over one. Further study evaluating combination treatment with azithromycin and <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> versus azithromycin alone is ongoing [<a href="#rid63">63</a>].  </p><p class="headingAnchor" id="H1191179315"><span class="h3">Fluoroquinolone-susceptible infection</span><span class="headingEndMark"> — </span>Fluoroquinolones are considered by many experts to be the drug of choice for susceptible isolates. Of the fluoroquinolones, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> and <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> are widely available and effective. <a class="drug drug_general" data-topicid="9710" href="/d/drug information/9710.html" rel="external">Norfloxacin</a> is very poorly absorbed and should not be used. If a fluoroquinolone cannot be used, alternatives include <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and third-generation cephalosporins. (See <a class="local">'Fluoroquinolone-nonsusceptible infection'</a> below.)</p><p>Fluoroquinolones are bactericidal, are concentrated intracellularly and in the bile, and result in rapid elimination of intracellular bacteria. They are more effective than beta-lactams against susceptible organisms. As an example, in an open-label randomized trial among patients older than 15 years, <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> (200 mg orally twice daily for five days) resulted in higher cure rates compared with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (3 g intravenously once daily for three days) [<a href="#rid64">64</a>]. In a separate open-label randomized trial of 82 children, resolution of fever occurred more rapidly (4.4 versus 8.5 days) with ofloxacin (10 mg/kg per day divided twice daily for five days) compared with <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> (20 mg/kg per day divided twice daily for seven days) [<a href="#rid65">65</a>]. There was one treatment failure in the ofloxacin group compared with 10 treatment failures and one relapse in the cefixime group.</p><p>Although fluoroquinolones are not recommended for routine use in children in the United States because of arthropathy and cartilage toxicity in exposed immature animals [<a href="#rid51">51,52</a>], clinical studies have not demonstrated sustained injury to developing bones or joints in children treated with available fluoroquinolones [<a href="#rid53">53,54</a>]. Thus, fluoroquinolone use in children is acceptable for a severe infection, such as enteric fever, when alternatives are not available or appropriate.</p><p class="headingAnchor" id="H897245437"><span class="h3">Fluoroquinolone-nonsusceptible infection</span><span class="headingEndMark"> — </span>Fluoroquinolone nonsusceptible infections include those with reduced susceptibility to the fluoroquinolones (ie, nalidixic acid-resistant) and those with frank resistance. In infections with reduced fluoroquinolone susceptibility, treatment with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> is associated with longer time to defervescence and higher rates of clinical treatment failure [<a href="#rid46">46,66</a>], and so should be avoided.</p><p>When fluoroquinolones cannot be used, we typically use <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>. If azithromycin cannot be used because of cost, availability, or other reasons, other options include third-generation cephalosporins and, if susceptibility is demonstrated, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, or <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azithromycin</strong> – <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> has good efficacy for enteric fever. In a systematic review that included seven randomized trials of adults and children with enteric fever, azithromycin was at least as effective as comparators (fluoroquinolones, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>) with regards to clinical failure, time to defervescence, and relapse [<a href="#rid67">67</a>]. For fluoroquinolone-nonsusceptible infection, azithromycin appears superior to <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a>. As an example, in an open-label, randomized study among Vietnamese adults and children with uncomplicated typhoid fever due to nalidixic acid-resistant or multidrug-resistant isolates, azithromycin (1 g daily for five days) resulted in a trend towards greater clinical cure rates (82 versus 64 percent), faster time to defervescence (mean 5.8 versus 8.2 days) and lower rates of post-treatment fecal carriage (1.6 versus 19 percent) [<a href="#rid68">68</a>]. Early convalescent fecal shedding may spread the organism in a community even if few of these individuals become chronic carriers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cephalosporins</strong> – Third-generation cephalosporins also have demonstrated efficacy but require a longer duration of therapy. Although the optimal duration has not been established, at least 10 to 14 days are warranted because of the risk of relapse with shorter durations [<a href="#rid49">49,69-71</a>]. In two randomized trials, seven days of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (50 to 75 mg/kg per day) resulted in relapse within four weeks in 14 percent of children [<a href="#rid69">69,70</a>]. In one of these studies, children were assigned to seven days of therapy with either <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (10 mg/kg per day; maximum 500 mg) or ceftriaxone (75 mg/kg per day; maximum 2.5 g per day) [<a href="#rid69">69</a>]. There were four relapses with ceftriaxone compared with none with azithromycin (14 versus 0 percent). </p><p></p><p class="bulletIndent1">Among the third-generation cephalosporins, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> may be superior to <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> [<a href="#rid72">72</a>]. Oral <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> has not been extensively compared directly with ceftriaxone, but appears to be of generally comparable efficacy [<a href="#rid49">49,71</a>]. Cefixime for 14 days was comparable to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> given for 7 days (93 versus 87 percent cure) in a study of children with uncomplicated enteric fever in Bangladesh [<a href="#rid73">73</a>]. However, other studies have reported a slower time to defervescence and a relatively high rate of on-treatment failure with cefixime compared with other agents [<a href="#rid65">65,74</a>]. </p><p></p><p>Although <a class="drug drug_general" data-topicid="8928" href="/d/drug information/8928.html" rel="external">gatifloxacin</a> had previously been proposed as an option for isolates with reduced susceptibility to fluoroquinolones (ie, nalidixic acid-resistant isolates) because it appeared to retain relatively good activity against them [<a href="#rid75">75-77</a>], the emergence of frankly fluoroquinolone-resistant isolates has limited its utility. Moreover, it is not widely available, having been withdrawn from most countries because of associated dysglycemia. </p><p>The rise and fall of <a class="drug drug_general" data-topicid="8928" href="/d/drug information/8928.html" rel="external">gatifloxacin</a> as an effective therapy for typhoid has been demonstrated in several trials from Nepal. In an analysis of four trials conducted between 2005 and 2014, gatifloxacin had equivalent or better fever clearance times in the first three trials when compared with <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>, <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, and <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> [<a href="#rid59">59</a>]. However, during the course of the trials, MICs to fluoroquinolones steadily rose, and these higher MICs were associated with slower time to defervescence with gatifloxacin. In the fourth randomized trial, which was conducted from 2011 to 2014 and included children and adults with documented or suspected enteric fever, treatment failure was similar with gatifloxacin versus <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, each given for seven days (15 and 16 percent, respectively) [<a href="#rid58">58</a>]. However, among those with culture-confirmed <em>S. </em>Typhi infection, 25 percent had fluoroquinolone-resistant isolates, and failure was greater with gatifloxacin (26 versus 7 percent). The trial was stopped early because of the high rates of fluoroquinolone resistance identified. Fluoroquinolones are therefore no longer considered appropriate empiric therapy for enteric fever in this region.</p><p class="headingAnchor" id="H8"><span class="h1">OTHER TREATMENT CONSIDERATIONS</span></p><p class="headingAnchor" id="H9"><span class="h2">Adjunctive corticosteroids for severe infection</span><span class="headingEndMark"> — </span>For patients with suspected or known enteric fever and severe systemic illness (delirium, obtundation, stupor, coma, or shock), we suggest adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (3 mg/kg followed by 1 mg/kg every 6 hours for a total of 48 hours). </p><p>In a randomized, prospective, double-blind study performed in Indonesia in the early 1980s among 38 adults and children with severe enteric fever (shock or obtundation), the addition of high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> to <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> treatment reduced mortality compared with chloramphenicol alone (10 versus 55 percent) [<a href="#rid78">78</a>]. Adjunctive corticosteroids did not increase the rate of other complications, carriage, or relapse. Subsequent observational studies have also supported the benefit [<a href="#rid79">79,80</a>], but whether the adjunctive dexamethasone is beneficial with other antibiotics or in different clinical settings remains uncertain. </p><p class="headingAnchor" id="H10"><span class="h2">Patients with ileal perforation</span><span class="headingEndMark"> — </span>For patients with ileal perforation, prompt surgical intervention is usually indicated, as is broader antimicrobial coverage to cover peritonitis and potential secondary bacteremia with enteric organisms (see  <a class="medical medical_review" href="/d/html/101694.html" rel="external">"Antimicrobial approach to intra-abdominal infections in adults"</a>). The extent of surgical intervention remains controversial; the best surgical procedure appears to be segmental resection of the involved intestine, when possible [<a href="#rid81">81,82</a>]. </p><p>In a retrospective review from West Africa including 112 patients undergoing laparotomy for typhoid perforation, most of the perforations were single (77 percent) and in the terminal ileum [<a href="#rid83">83</a>]. Primary repair was successful in 84 percent of cases, although reoperative management was required in some patients who did not respond immediately. Even with surgery, mortality rates of 14, 16, and 34 percent have been reported in series from Nigeria, Togo, and the Ivory Coast, respectively [<a href="#rid83">83-85</a>].</p><p class="headingAnchor" id="H3656469298"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Successful treatment in uncomplicated cases usually results in clinical improvement within three to five days. In most clinical trials, the mean time to defervescence is four to six days, so persistent fevers of this duration following treatment initiation does not imply therapeutic failure. Patients should be subsequently monitored for or instructed to report recurrent symptoms, which could reflect relapse. </p><p class="headingAnchor" id="H11"><span class="h2">Relapse</span><span class="headingEndMark"> — </span>Relapse of enteric fever after clinical cure can occur in immunocompetent individuals; in such cases, it typically occurs two to three weeks after resolution of fever. The risk of relapse depends on the antibiotic used to treat the initial infection. Relapse rates with <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, a bacteriostatic agent, were 10 to 25 percent, but subsequent studies that have included multidrug-resistant <em>S. </em>Typhi infections and newer antibiotics have noted lower relapse rates of 1 to 6 percent [<a href="#rid49">49,65,76</a>]. </p><p>Relapsed infection should be treated with an additional course of antibiotics, guided by susceptibility testing. Usually, the isolate has the same susceptibility pattern as the initial infection. A longer treatment course with a third-generation cephalosporin is also reasonable.</p><p class="headingAnchor" id="H1794475070"><span class="h2">Post-acute shedding and chronic carriage</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication for evaluation</strong> – Evaluation for <em>S.</em> Typhi (or <em>S. </em>Paratyphi A) post-acute shedding or carriage is warranted for individuals at increased risk for transmission to others; these include food handlers, healthcare workers, childcare workers, and children in daycare. Specific policies on who should be screened vary by local health ordinances. Some states in the United States, for example, require screening follow acute typhoid illness for all individuals and their contacts, while other states only require screening for high-risk groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-acute stool shedding</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definition and risk factors</strong> – Surveillance studies of patients with acute typhoid fever have shown that up to 10 percent of untreated individuals shed bacteria in their stool up to three months post-infection [<a href="#rid1">1</a>]. With antibiotic treatment, approximately 5 percent of children continue to sh<em>e</em>d <em>S</em>. Typhi 30 days after onset of fever [<a href="#rid86">86,87</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening approach </strong>–<strong> </strong>To document clearance of post-acute stool shedding, samples are typically collected at least one week after discontinuation of antibiotics and at least one month after illness onset. Typically, three stool (with or without urine) samples are collected at least 24 hours apart. If any cultures are positive, repeat cultures should be performed monthly until there are three consecutive negative samples.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic carriage</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definition and risk factors</strong> – Chronic carriage of Salmonellae is defined as excretion of the organism in stool for more than 12 months after the acute infection. Chronic carriage rates after<em> S. </em>Typhi infection range from 1 to 6 percent [<a href="#rid88">88</a>]. Risk factors include older age (&gt;50 years), female sex, gallbladder abnormalities, and gallstones [<a href="#rid89">89,90</a>]. Risk factors for chronic urinary carriage include kidney stones and schistosomal infection [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/d/html/2491.html" rel="external">"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis", section on 'Salmonella'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening approach </strong>– At least three stool samples should be collected, separated by at least 24 hours; the estimated sensitivity is 70 to 80 percent [<a href="#rid91">91</a>]. Serologic screening is not recommended for identifying chronic carriers; some studies have identified high levels of anti-Vi or anti-YncE antibodies in chronic carriers, though specificity appears to vary by setting. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management  </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Clinical approach</strong> – Management of chronic carriage generally consists of antimicrobial therapy. If eradication is not achieved with antimicrobial therapy, cholecystectomy may be warranted. The effectiveness of cholecystectomy in eradicating carriage is around 70 to 80 percent. The efficacy may be better with combined antibiotic and surgical management; however, available data are decades old [<a href="#rid92">92,93</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Antibiotic selection</strong> – For patients with a fluoroquinolone-susceptible isolate, treatment with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 to 750 mg orally twice daily) or <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> (500 mg orally once daily) for four weeks is reasonable. Four weeks after completion of therapy, we obtain at least three stool samples for culture [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent3">For patients with a fluoroquinolone-nonsusceptible isolate, treatment should be guided by susceptibility data; possible regimens include high-dose <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (eg, 75 to 100 mg/kg per day) for six weeks or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (160 mg/800 mg orally twice daily) for three months [<a href="#rid95">95-99</a>].</p><p></p><p class="bulletIndent3">This approach is supported by a 2022 systematic review including 8 studies and 126 patients with enteric fever treated with fluoroquinolones or beta-lactams (<a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> or <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>); successful eradication was achieved more frequently with fluoroquinolones (92 versus 68 percent) [<a href="#rid100">100</a>]. However, only one study was randomized and blinded, and the other studies included no control group; in addition, the trials were done prior to widespread antimicrobial resistance. </p><p></p><p class="headingAnchor" id="H3319756200"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Effective antibiotic therapy has dramatically impacted the outcomes of enteric fever. In the pre-antibiotic era, mortality rates were 15 percent or greater [<a href="#rid101">101,102</a>] and survivors experienced a prolonged illness lasting weeks, with months of subsequent debilitation. Approximately 10 percent of untreated patients relapsed and up to 4 percent become chronic carriers of the organism. </p><p>Among those receiving medical care in the post-antibiotic era, the average mortality rate from enteric fever is estimated to be less than 1 percent [<a href="#rid1">1</a>]. Although a 2018 systematic review reported a higher case-fatality rate, it was likely an overestimate of contemporary mortality rates, as high rates were seen primarily in older or smaller studies [<a href="#rid103">103</a>]. Mortality rates from more recent studies are low. As an example, in a study of nearly 3000 individuals receiving care for culture-confirmed enteric fever in Pakistan from 2012 to 2014, there were no deaths reported [<a href="#rid104">104</a>]. In the United States, a Centers for Disease Control and Prevention compilation of 10 hospital-based typhoid fever series reported a mean case-fatality rate of 2 percent (range 0 to 14.8 percent), but noted that these series capture only the most severe and hospitalized cases in those with access to care [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H13"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H887847740"><span class="h2">Food and water safety</span><span class="headingEndMark"> — </span>Enteric fever results from the ingestion of contaminated food or water. The inoculum in food is likely higher than that in contaminated water. Access to fresh water, prioritization of sanitation and hygiene, and education about food and water safety are essential preventive strategies. </p><p>For travelers, the main mechanism of transmission is ingestion of the local cuisine or water in areas where sanitation and personal hygiene may be poor. Travelers should be advised on behavioral precautions. (See  <a class="medical medical_review" href="/d/html/3898.html" rel="external">"Travel advice", section on 'Food and water'</a>.) </p><p class="headingAnchor" id="H2864621242"><span class="h2">Vaccination</span></p><p class="headingAnchor" id="H3714985374"><span class="h3">In endemic areas</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) recommends implementation of national typhoid vaccination programs as part of broader control efforts in settings where typhoid is endemic. Of available vaccines, it prefers typhoid conjugate vaccines for their efficacy and established safety in infants and young children, as well as their greater and more durable immunogenicity compared with other vaccines [<a href="#rid106">106</a>]. It recommends administration of typhoid conjugate vaccine for infants and children six months of age or older, with catch-up vaccination campaigns, if possible, for children up to 15 years old. (See <a class="local">'Licensed vaccines'</a> below.) </p><p class="headingAnchor" id="H1293476352"><span class="h3">In nonendemic areas</span><span class="headingEndMark"> — </span>Typhoid vaccination is indicated in travelers to endemic areas and other individuals with risk for exposure, but available vaccines are not entirely protective. Specific indications and vaccine options vary by country. </p><p>In the United States, typhoid vaccination is recommended for travelers (even short-term travelers) to areas where there is risk of exposure to <em>S. </em>Typhi<em>, </em>for individuals with intimate exposure to a documented <em>S. </em>Typhi chronic carrier (eg, household contacts), and for individuals whose work exposes them to cultures or specimens containing <em>S</em>. Typhi (eg, laboratory workers) [<a href="#rid107">107</a>]. Typhoid conjugate vaccine is not yet available in the United States. Either the polysaccharide or oral vaccine formulation is appropriate, although the oral vaccine should be avoided in immunocompromised and pregnant individuals since it is a live vaccine. If repeated exposure to <em>S. </em>Typhi<em> </em>is expected, repeat typhoid vaccination is advised to maintain immunity. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Typhoid vaccine'</a>.)</p><p>Vaccination is appropriate even in those who have a history of enteric fever, particularly in those not living in endemic areas, if re-exposure is expected. Natural infection does not provide complete protection against recurrent illness (which is not the same as relapsed infection). One study suggests early treatment of natural infection may blunt humoral responses to capsular antigens [<a href="#rid108">108</a>]. The optimal timing for vaccination following clinical illness is not known. </p><p class="headingAnchor" id="H14"><span class="h3">Licensed vaccines</span><span class="headingEndMark"> — </span>Several typhoid vaccines have been licensed, although they are not all universally available. None are completely effective against <em>S. </em>Typhi and none have been demonstrated to provide protection against paratyphoid fever caused by <em>S. </em>Paratyphi A. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vi typhoid conjugate vaccines (TCV)</strong> – These vaccines consist of the Vi polysaccharide antigen linked to various carrier proteins. Typbar-TCV, a Vi-TT (tetanus toxoid) conjugate, is the representative vaccine of this type; it is administered as a single intramuscular dose. The need for revaccination for continued protection is uncertain. It is licensed in India, Nepal, and several other countries, but it is not yet available in Europe or the United States. A second typhoid conjugate vaccine (Typhibev), containing Vi conjugated to CRM<sub>197</sub>, a nontoxic mutant of diphtheria toxin, was prequalified in December 2020. This vaccine demonstrated safety and noninferior immunogenicity in clinical trials [<a href="#rid109">109</a>] but has not yet been evaluated for clinical efficacy. A Vi-DT (diphtheria toxin) vaccine was found to have noninferior immunogenicity in a Phase 3 trial in Nepal [<a href="#rid110">110</a>]. Two other Vi-TT conjugate typhoid vaccines (PedaTyph and ZyVac-TCV) are available in India [<a href="#rid111">111</a>]. </p><p></p><p class="bulletIndent1">Emerging evidence suggests good efficacy of TCVs. In several randomized trials from Nepal, Bangladesh, and Malawi, which together included over 100,000 children, vaccine efficacy of Typbar-TCV against culture-confirmed typhoid fever ranged from 81 to 85 percent compared with control vaccines [<a href="#rid112">112-114</a>]. As an example, in the trial from Nepal, among over 20,000 children aged 9 months to 16 years, the incidence of typhoid fever over the year following Typbar-TCV vaccination was 79 cases compared with 428 cases per 100,000 person-years after meningococcal conjugate vaccination (vaccine efficacy 82 percent, 95% CI 59-92) [<a href="#rid112">112</a>]. Typbar-TCV was 97 percent (95% CI 95-98) effective against extensively drug-resistant (XDR) <em>S.</em> Typhi [<a href="#rid115">115</a>]. No major vaccine-associated adverse events were identified in any of the trials.</p><p></p><p class="bulletIndent1">Conjugate vaccines appear to be more immunogenic and better at inducing long-term memory responses compared with other typhoid vaccines [<a href="#rid116">116-118</a>]. In a randomized trial of individuals aged 2 to 45 years in India, the conjugate vaccine (Typbar-TCV) resulted in higher seroconversion rates and higher antibody titers after three to five years than the polysaccharide vaccine, especially in young children [<a href="#rid117">117</a>]. It was also safe and immunogenic in a parallel open-label trial of children aged 6 to 23 months, with anti-Vi IgG antibodies persisting up to five years in approximately 85 percent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vi polysaccharide vaccine</strong> – This consists of the Vi polysaccharide antigen. It is administered as a single intramuscular dose. It can also be given subcutaneously. If continued protection is needed, revaccination is recommended every two to three years. </p><p></p><p class="bulletIndent1">In a systematic review and meta-analysis of randomized controlled trials, efficacy at one, two, and three years was 69, 59, and 55 percent [<a href="#rid119">119</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ty21a vaccine</strong> – This is a live oral vaccine that consists of an attenuated <em>S</em>. Typhi strain Ty21a. It is administered in three to four doses taken on alternate days. If continued protection is needed, revaccination is recommended every three to five years.</p><p></p><p class="bulletIndent1">In a systematic review and meta-analysis of randomized controlled trials, efficacy at one, two, and three years was 45, 59, and 56 percent [<a href="#rid119">119</a>]. There is some evidence that the Ty21a vaccine may confer partial protection against <em>S. </em>Paratyphi B [<a href="#rid120">120</a>]. </p><p></p><p class="bulletIndent1">Adverse effects associated with these vaccines are generally mild (eg, fever or injection site pain or swelling) [<a href="#rid112">112,117,120</a>]. </p><p></p><p class="headingAnchor" id="H971942388"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109942.html" rel="external">"Society guideline links: Acute diarrhea in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/110029.html" rel="external">"Society guideline links: Acute diarrhea in children"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115404.html" rel="external">"Society guideline links: Travel medicine"</a>.)</p><p class="headingAnchor" id="H23221301"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83903.html" rel="external">"Patient education: Enteric (typhoid and paratyphoid) fever (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18655300"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial resistance</strong> – Treatment of enteric fever has been complicated by the development of antimicrobial resistance. In particular, resistance to clinically important fluoroquinolones has become a major problem worldwide, particularly in Asia. Most <em>Salmonella</em> Typhi and <em>Salmonella </em>Paratyphi isolates remain susceptible to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and third-generation cephalosporins. However, an extensively drug-resistant (XDR) isolate has emerged in Pakistan that is resistant to many agents, including third-generation cephalosporins and fluoroquinolones. (See <a class="local">'Antimicrobial resistance'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection</strong> – Antibiotic selection depends upon the severity of illness, local resistance patterns, whether oral medications are feasible, the clinical setting, and available resources  (<a class="graphic graphic_table graphicRef109995" href="/d/graphic/109995.html" rel="external">table 1</a>). (See <a class="local">'Antimicrobial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe or complicated disease</strong> – Patients with severe disease (systemic toxicity, depressed consciousness, prolonged fever, organ system dysfunction, or other feature that prompts hospitalization) should be treated initially with a parenteral antibiotic. For such patients, who have acquired infection outside of Pakistan or Iraq, we suggest <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Alternatives include <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> or, if the risk of decreased susceptibility to fluoroquinolones is low (eg, disease not acquired from South Asia or Iraq), a parenteral fluoroquinolone. </p><p></p><p class="bulletIndent2">If there is suspicion for <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> resistance, a carbapenem can be used while awaiting susceptibility testing. For patients with severe typhoid fever acquired in Pakistan or Iraq, we suggest empiric therapy with a carbapenem (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>) because of the risk of ceftriaxone-resistant and XDR typhoid (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Severe or complicated disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uncomplicated disease</strong> – For patients with uncomplicated enteric fever, antibiotic selection depends on the likelihood of reduced susceptibility to fluoroquinolones, which is highest in infections acquired in South Asia. In the absence of known or suspected reduced fluoroquinolone susceptibility, we suggest antibiotic therapy with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). </p><p></p><p class="bulletIndent2">For patients with uncomplicated enteric fever due to an isolate known or suspected to have reduced fluoroquinolone susceptibility (including patients with infection acquired in Pakistan), we suggest <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> is an alternative (except for patients with infection acquired in Pakistan or Iraq). With increasing reports of azithromycin-resistant <em>S. </em>Typhi from South Asia, susceptibility testing should be performed. (See <a class="local">'Uncomplicated disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Directed therapy</strong> – Empiric antibiotic regimens can be adjusted if and when formal sensitivities are available. (See <a class="local">'Directed therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive corticosteroids for severe infection</strong> – For patients with suspected or known enteric fever and severe systemic illness (delirium, obtundation, stupor, coma, or shock), we suggest adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (3 mg/kg followed by 1 mg/kg every 6 hours for a total of 48 hours) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Adjunctive corticosteroids for severe infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with ileal perforation</strong> – Treatment of ileal perforation warrants surgical therapy in addition to antibiotic therapy to cover both enteric fever and enteric organisms. (See <a class="local">'Patients with ileal perforation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> – Successful treatment in uncomplicated cases usually results in clinical improvement within three to five days, with fever clearance at four to six days. Relapse of enteric fever after clinical cure can occur two to three weeks after resolution of illness and should be treated with an additional course of antibiotics, guided by susceptibility testing. (See <a class="local">'Relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic carriage</strong> – Chronic<em> Salmonella</em> carriage is defined as excretion of the organism in stool &gt;12 months after acute infection. (See <a class="local">'Post-acute shedding and chronic carriage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indication for evaluation</strong> – Evaluation for post-acute <em>S.</em> Typhi shedding or carriage is warranted for individuals at increased risk for transmission to others; these include food handlers, health care workers, children in daycare, and childcare workers.  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – For chronic <em>Salmonella</em> carriers who are at increased risk for transmission to others (such as food handlers, health care workers, and childcare workers), we suggest antibiotic treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); for those with fluoroquinolone-susceptible isolates, we suggest treatment with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Food and water safety</strong> – Enteric fever results from the ingestion of contaminated food or water; attention to food safety is important for travelers to regions where sanitation and personal hygiene may be poor. (See <a class="local">'Food and water safety'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaccination </strong>– (see <a class="local">'Vaccination'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Three vaccines are available globally for protection against <em>S. </em>Typhi: parenteral Vi polysaccharide vaccine, live oral <em>S. </em>Typhi vaccine strain Ty21a, and parenteral Vi conjugate vaccine. None of these vaccines offer complete protection, and periodic revaccination is needed if exposure risk continues. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In endemic areas, the World Health Organization (WHO) recommends implementation of national typhoid vaccination programs, preferably with a conjugate <a class="drug drug_general" data-topicid="10030" href="/d/drug information/10030.html" rel="external">typhoid vaccine</a>, as part of broader control efforts. The conjugate vaccine is not available in the United States or Europe. </p><p></p><p class="headingAnchor" id="H4142670934"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Elizabeth L. Hohmann, MD, and Edward T Ryan, MD, DTMH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med 2002; 347:1770.</a></li><li><a class="nounderline abstract_t">Vollaard AM, Ali S, Widjaja S, et al. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg 2005; 99:440.</a></li><li><a class="nounderline abstract_t">Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 2012; 55:1107.</a></li><li class="breakAll">EUCAST. Clinical breakpoints - breakpoints and guidance. https://www.eucast.org/clinical_breakpoints/ (Accessed on November 02, 2020).</li><li class="breakAll">CLSI. M100 online. http://em100.edaptivedocs.net/dashboard.aspx (Accessed on November 02, 2020).</li><li><a class="nounderline abstract_t">Barkume C, Date K, Saha SK, et al. Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP): An Overview and Lessons Learned. J Infect Dis 2018; 218:S188.</a></li><li><a class="nounderline abstract_t">Al-Emran HM, Eibach D, Krumkamp R, et al. A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa. Clin Infect Dis 2016; 62 Suppl 1:S42.</a></li><li><a class="nounderline abstract_t">International Typhoid Consortium, Wong VK, Holt KE, et al. Molecular Surveillance Identifies Multiple Transmissions of Typhoid in West Africa. PLoS Negl Trop Dis 2016; 10:e0004781.</a></li><li><a class="nounderline abstract_t">Britto CD, Wong VK, Dougan G, Pollard AJ. A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Negl Trop Dis 2018; 12:e0006779.</a></li><li><a class="nounderline abstract_t">Pham Thanh D, Karkey A, Dongol S, et al. A novel ciprofloxacin-resistant subclade of H58 Salmonella Typhi is associated with fluoroquinolone treatment failure. Elife 2016; 5:e14003.</a></li><li><a class="nounderline abstract_t">Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008; 21:531.</a></li><li><a class="nounderline abstract_t">Karki S, Shakya P, Cheng AC, et al. Trends of etiology and drug resistance in enteric fever in the last two decades in Nepal: a systematic review and meta-analysis. Clin Infect Dis 2013; 57:e167.</a></li><li><a class="nounderline abstract_t">Harish BN, Madhulika U, Parija SC. Isolated high-level ciprofloxacin resistance in Salmonella enterica subsp. enterica serotype Paratyphi A. J Med Microbiol 2004; 53:819.</a></li><li><a class="nounderline abstract_t">Renuka K, Sood S, Das BK, Kapil A. High-level ciprofloxacin resistance in Salmonella enterica serotype Typhi in India. J Med Microbiol 2005; 54:999.</a></li><li><a class="nounderline abstract_t">Mohanty S, Gaind R, Paglietti B, et al. Bacteraemia with pleural effusions complicating typhoid fever caused by high-level ciprofloxacin-resistant Salmonella enterica serotype Typhi. Ann Trop Paediatr 2010; 30:233.</a></li><li><a class="nounderline abstract_t">Bayramoglu G, Ozgumus OB, Kolayli F, et al. [Molecular epidemiology, antimicrobial resistance and characterization of extended-spectrum beta-lactamases of Salmonella enterica serotype Paratyphi B clinical isolates]. Mikrobiyol Bul 2014; 48:191.</a></li><li><a class="nounderline abstract_t">González-López JJ, Piedra-Carrasco N, Salvador F, et al. ESBL-producing Salmonella enterica serovar Typhi in traveler returning from Guatemala to Spain. Emerg Infect Dis 2014; 20:1918.</a></li><li><a class="nounderline abstract_t">Pokharel BM, Koirala J, Dahal RK, et al. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int J Infect Dis 2006; 10:434.</a></li><li><a class="nounderline abstract_t">François Watkins LK, Winstead A, Appiah GD, et al. Update on Extensively Drug-Resistant Salmonella Serotype Typhi Infections Among Travelers to or from Pakistan and Report of Ceftriaxone-Resistant Salmonella Serotype Typhi Infections Among Travelers to Iraq - United States, 2018-2019. MMWR Morb Mortal Wkly Rep 2020; 69:618.</a></li><li><a class="nounderline abstract_t">Argimón S, Nagaraj G, Shamanna V, et al. Circulation of Third-Generation Cephalosporin Resistant Salmonella Typhi in Mumbai, India. Clin Infect Dis 2022; 74:2234.</a></li><li><a class="nounderline abstract_t">Samajpati S, Pragasam AK, Mandal S, et al. Emergence of ceftriaxone resistant Salmonella enterica serovar Typhi in Eastern India. Infect Genet Evol 2021; 96:105093.</a></li><li><a class="nounderline abstract_t">Jacob JJ, Pragasam AK, Vasudevan K, et al. Salmonella Typhi acquires diverse plasmids from other Enterobacteriaceae to develop cephalosporin resistance. Genomics 2021; 113:2171.</a></li><li><a class="nounderline abstract_t">Parry CM, Thieu NT, Dolecek C, et al. Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. Antimicrob Agents Chemother 2015; 59:2756.</a></li><li><a class="nounderline abstract_t">Molloy A, Nair S, Cooke FJ, et al. First report of Salmonella enterica serotype paratyphi A azithromycin resistance leading to treatment failure. J Clin Microbiol 2010; 48:4655.</a></li><li><a class="nounderline abstract_t">Iqbal J, Dehraj IF, Carey ME, et al. A Race against Time: Reduced Azithromycin Susceptibility in Salmonella enterica Serovar Typhi in Pakistan. mSphere 2020; 5.</a></li><li><a class="nounderline abstract_t">Carey ME, Jain R, Yousuf M, et al. Spontaneous Emergence of Azithromycin Resistance in Independent Lineages of Salmonella Typhi in Northern India. Clin Infect Dis 2021; 72:e120.</a></li><li><a class="nounderline abstract_t">Sajib MSI, Tanmoy AM, Hooda Y, et al. Tracking the Emergence of Azithromycin Resistance in Multiple Genotypes of Typhoidal Salmonella. mBio 2021; 12.</a></li><li><a class="nounderline abstract_t">Hooda Y, Sajib MSI, Rahman H, et al. Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in Bangladesh identified through passive pediatric surveillance. PLoS Negl Trop Dis 2019; 13:e0007868.</a></li><li><a class="nounderline abstract_t">Kariuki S, Gordon MA, Feasey N, Parry CM. Antimicrobial resistance and management of invasive Salmonella disease. Vaccine 2015; 33 Suppl 3:C21.</a></li><li><a class="nounderline abstract_t">Yan M, Li X, Liao Q, et al. The emergence and outbreak of multidrug-resistant typhoid fever in China. Emerg Microbes Infect 2016; 5:e62.</a></li><li><a class="nounderline abstract_t">Hendriksen RS, Leekitcharoenphon P, Lukjancenko O, et al. Genomic signature of multidrug-resistant Salmonella enterica serovar typhi isolates related to a massive outbreak in Zambia between 2010 and 2012. J Clin Microbiol 2015; 53:262.</a></li><li><a class="nounderline abstract_t">Wain J, Hendriksen RS, Mikoleit ML, et al. Typhoid fever. Lancet 2015; 385:1136.</a></li><li><a class="nounderline abstract_t">Rahman BA, Wasfy MO, Maksoud MA, et al. Multi-drug resistance and reduced susceptibility to ciprofloxacin among Salmonella enterica serovar Typhi isolates from the Middle East and Central Asia. New Microbes New Infect 2014; 2:88.</a></li><li><a class="nounderline abstract_t">Marks F, von Kalckreuth V, Aaby P, et al. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 2017; 5:e310.</a></li><li><a class="nounderline abstract_t">Qamar FN, Yousafzai MT, Dehraj IF, et al. Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019. Clin Infect Dis 2020; 71:S276.</a></li><li><a class="nounderline abstract_t">Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet 2015; 47:632.</a></li><li><a class="nounderline abstract_t">Dutta S, Das S, Mitra U, et al. Antimicrobial resistance, virulence profiles and molecular subtypes of Salmonella enterica serovars Typhi and Paratyphi A blood isolates from Kolkata, India during 2009-2013. PLoS One 2014; 9:e101347.</a></li><li><a class="nounderline abstract_t">Veeraraghavan B, Pragasam AK, Ray P, et al. Evaluation of Antimicrobial Susceptibility Profile in Salmonella Typhi and Salmonella Paratyphi A: Presenting the Current Scenario in India and Strategy for Future Management. J Infect Dis 2021; 224:S502.</a></li><li><a class="nounderline abstract_t">Date KA, Newton AE, Medalla F, et al. Changing Patterns in Enteric Fever Incidence and Increasing Antibiotic Resistance of Enteric Fever Isolates in the United States, 2008-2012. Clin Infect Dis 2016; 63:322.</a></li><li><a class="nounderline abstract_t">Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins. mBio 2018; 9.</a></li><li><a class="nounderline abstract_t">Qamar FN, Yousafzai MT, Khalid M, et al. Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study. Lancet Infect Dis 2018; 18:1368.</a></li><li class="breakAll">Extensively Drug-Resistant Typhoid Fever in Pakistan https://wwwnc.cdc.gov/travel/notices/alert/xdr-typhoid-fever-pakistan (Accessed on July 16, 2018).</li><li><a class="nounderline abstract_t">Chatham-Stephens K, Medalla F, Hughes M, et al. Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018. MMWR Morb Mortal Wkly Rep 2019; 68:11.</a></li><li class="breakAll">World Health Organization, Regional Office for Eastern Mediterranean, Cairo, Egypt. Weekly Epidemiological Monitor, December 2018. http://applications.emro.who.int/docs/epi/2018/Epi_Monitor_2018_11_52.pdf?ua=1 (Accessed on January 10, 2019).</li><li class="breakAll">Centers for Disease Control and Prevention. Health Alert Network: Extensively Drug-Resistant Salmonella Typhi Infections Among U.S. Residents Without International Travel. https://emergency.cdc.gov/han/2021/han00439.asp (Accessed on February 23, 2021).</li><li><a class="nounderline abstract_t">Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404.</a></li><li><a class="nounderline abstract_t">Limson BM. Short course quinolone therapy of typhoid fever in developing countries. Drugs 1995; 49 Suppl 2:136.</a></li><li><a class="nounderline abstract_t">Thaver D, Zaidi AK, Critchley J, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2005; :CD004530.</a></li><li><a class="nounderline abstract_t">Girgis NI, Sultan Y, Hammad O, Farid Z. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Pediatr Infect Dis J 1995; 14:603.</a></li><li><a class="nounderline abstract_t">Gotuzzo E, Echevarría J, Carrillo C, et al. Randomized comparison of aztreonam and chloramphenicol in treatment of typhoid fever. Antimicrob Agents Chemother 1994; 38:558.</a></li><li><a class="nounderline abstract_t">Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.</a></li><li><a class="nounderline abstract_t">Schaad U. Toxicity of quinolones in paediatric patients. Adv Antimicrob Antineoplast Chemother 1992; 11:259.</a></li><li><a class="nounderline abstract_t">Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.</a></li><li class="breakAll">American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2018-2021 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.903.</li><li><a class="nounderline abstract_t">Asna SM, Haq JA, Rahman MM. Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 2003; 56:32.</a></li><li><a class="nounderline abstract_t">Slinger R, Desjardins M, McCarthy AE, et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis 2004; 4:36.</a></li><li><a class="nounderline abstract_t">Kadhiravan T, Wig N, Kapil A, et al. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis 2005; 5:37.</a></li><li><a class="nounderline abstract_t">Arjyal A, Basnyat B, Nhan HT, et al. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. Lancet Infect Dis 2016; 16:535.</a></li><li><a class="nounderline abstract_t">Thompsom CN, Karkey A, Dongol S, et al. Treatment response in enteric fever in an era of increasing antimicrobial resistance: an individual patient data analysis of 2,092 participants enrolled into four randomised controlled trials in Nepal. Clin Infect Dis 2017.</a></li><li><a class="nounderline abstract_t">Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 2010; 50:241.</a></li><li><a class="nounderline abstract_t">Parry CM, Thuy CT, Dongol S, et al. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2010; 54:5201.</a></li><li><a class="nounderline abstract_t">Meltzer E, Stienlauf S, Leshem E, et al. A large outbreak of Salmonella Paratyphi A infection among israeli travelers to Nepal. Clin Infect Dis 2014; 58:359.</a></li><li><a class="nounderline abstract_t">Giri A, Karkey A, Dongol S, et al. Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol. Wellcome Open Res 2021; 6:207.</a></li><li><a class="nounderline abstract_t">Smith MD, Duong NM, Hoa NT, et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 1994; 38:1716.</a></li><li><a class="nounderline abstract_t">Cao XT, Kneen R, Nguyen TA, et al. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr Infect Dis J 1999; 18:245.</a></li><li><a class="nounderline abstract_t">Parry CM. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 2004; 98:413.</a></li><li><a class="nounderline abstract_t">Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008; :CD006083.</a></li><li><a class="nounderline abstract_t">Parry CM, Ho VA, Phuong le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 2007; 51:819.</a></li><li><a class="nounderline abstract_t">Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 2000; 31:1134.</a></li><li><a class="nounderline abstract_t">Bhutta ZA, Khan IA, Shadmani M. Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob Agents Chemother 2000; 44:450.</a></li><li><a class="nounderline abstract_t">Bhutta ZA, Khan IA, Molla AM. Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone. Pediatr Infect Dis J 1994; 13:990.</a></li><li><a class="nounderline abstract_t">Bhutta ZA. Therapeutic aspects of typhoidal salmonellosis in childhood: the Karachi experience. Ann Trop Paediatr 1996; 16:299.</a></li><li><a class="nounderline abstract_t">Begum B, Haque MA, Ahmed MS, et al. Comparison between azithromycin and cefixime in the treatment of typhoid fever in children. Mymensingh Med J 2014; 23:441.</a></li><li><a class="nounderline abstract_t">Pandit A, Arjyal A, Day JN, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One 2007; 2:e542.</a></li><li><a class="nounderline abstract_t">Arjyal A, Basnyat B, Koirala S, et al. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. Lancet Infect Dis 2011; 11:445.</a></li><li><a class="nounderline abstract_t">Dolecek C, Tran TP, Nguyen NR, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS One 2008; 3:e2188.</a></li><li><a class="nounderline abstract_t">Koirala S, Basnyat B, Arjyal A, et al. Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial. PLoS Negl Trop Dis 2013; 7:e2523.</a></li><li><a class="nounderline abstract_t">Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984; 310:82.</a></li><li><a class="nounderline abstract_t">Chisti MJ, Bardhan PK, Huq S, et al. High-dose intravenous dexamethasone in the management of diarrheal patients with enteric fever and encephalopathy. Southeast Asian J Trop Med Public Health 2009; 40:1065.</a></li><li><a class="nounderline abstract_t">Punjabi NH, Hoffman SL, Edman DC, et al. Treatment of severe typhoid fever in children with high dose dexamethasone. Pediatr Infect Dis J 1988; 7:598.</a></li><li><a class="nounderline abstract_t">Ameh EA, Dogo PM, Attah MM, Nmadu PT. Comparison of three operations for typhoid perforation. Br J Surg 1997; 84:558.</a></li><li><a class="nounderline abstract_t">Nasir AA, Abdur-Rahman LO, Adeniran JO. Predictor of mortality in children with typhoid intestinal perforation in a Tertiary Hospital in Nigeria. Pediatr Surg Int 2011; 27:1317.</a></li><li><a class="nounderline abstract_t">Saxe JM, Cropsey R. Is operative management effective in treatment of perforated typhoid? Am J Surg 2005; 189:342.</a></li><li><a class="nounderline abstract_t">Kouame J, Kouadio L, Turquin HT. Typhoid ileal perforation: surgical experience of 64 cases. Acta Chir Belg 2004; 104:445.</a></li><li><a class="nounderline abstract_t">Ugwu BT, Yiltok SJ, Kidmas AT, Opaluwa AS. Typhoid intestinal perforation in north central Nigeria. West Afr J Med 2005; 24:1.</a></li><li><a class="nounderline abstract_t">Srinivasan M, Sindhu KN, Giri S, et al. Salmonella Typhi Shedding and Household Transmission by Children With Blood Culture-Confirmed Typhoid Fever in Vellore, South India. J Infect Dis 2021; 224:S593.</a></li><li><a class="nounderline abstract_t">Khanam F, Darton TC, Meiring JE, et al. Salmonella Typhi Stool Shedding by Patients With Enteric Fever and Asymptomatic Chronic Carriers in an Endemic Urban Setting. J Infect Dis 2021; 224:S759.</a></li><li><a class="nounderline abstract_t">Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis 1982; 146:724.</a></li><li><a class="nounderline abstract_t">Gal-Mor O. Persistent Infection and Long-Term Carriage of Typhoidal and Nontyphoidal Salmonellae. Clin Microbiol Rev 2019; 32.</a></li><li><a class="nounderline abstract_t">Hofmann E, Chianale J, Rollán A, et al. Blood group antigen secretion and gallstone disease in the Salmonella typhi chronic carrier state. J Infect Dis 1993; 167:993.</a></li><li><a class="nounderline abstract_t">BOKKENHEUSER V. DETECTION OF TYPHOID CARRIERS. Am J Public Health Nations Health 1964; 54:477.</a></li><li><a class="nounderline abstract_t">Dinbar A, Altmann G, Tulcinsky DB. The treatment of chronic biliary salmonella carriers. Am J Med 1969; 47:236.</a></li><li><a class="nounderline abstract_t">Ristori C, Rodríguez H, Vicent P, et al. Persistence of the Salmonella typhi-paratyphi carrier state after gallbladder removal. Bull Pan Am Health Organ 1982; 16:361.</a></li><li><a class="nounderline abstract_t">Gotuzzo E, Guerra JG, Benavente L, et al. Use of norfloxacin to treat chronic typhoid carriers. J Infect Dis 1988; 157:1221.</a></li><li><a class="nounderline abstract_t">Simon HJ, Miller RC. Ampicillin in the treatment of chronic typhoid carriers. Report on fifteen treated cases and a review of the literature. N Engl J Med 1966; 274:807.</a></li><li><a class="nounderline abstract_t">Farid Z, Bassily S, Mikhail IA, et al. Treatment of chronic enteric fever with amoxicillin. J Infect Dis 1975; 132:698.</a></li><li><a class="nounderline abstract_t">Nolan CM, White PC Jr. Treatment of typhoid carriers with amoxicillin. Correlates of successful therapy. JAMA 1978; 239:2352.</a></li><li><a class="nounderline abstract_t">Iwarson S. Long-term co- trimoxazole treatment of chronic Salmonella carriers. Scand J Infect Dis 1977; 9:297.</a></li><li><a class="nounderline abstract_t">Freerksen E, Rosenfeld M, Freerksen R, Krüger-Thiemer M. Treatment of chronic salmonella carriers. Study with 40 cases of S. typhi, 19 cases of S. paratyphi b and 28 cases of S. enteritidis strains. Chemotherapy 1977; 23:192.</a></li><li><a class="nounderline abstract_t">McCann N, Scott P, Parry CM, Brown M. Antimicrobial agents for the treatment of enteric fever chronic carriage: A systematic review. PLoS One 2022; 17:e0272043.</a></li><li><a class="nounderline abstract_t">STUART BM, PULLEN RL. Typhoid; clinical analysis of 360 cases. Arch Intern Med (Chic) 1946; 78:629.</a></li><li><a class="nounderline abstract_t">WOODWARD TE, SMADEL JE. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med 1948; 29:131.</a></li><li><a class="nounderline abstract_t">Pieters Z, Saad NJ, Antillón M, et al. Case Fatality Rate of Enteric Fever in Endemic Countries: A Systematic Review and Meta-analysis. Clin Infect Dis 2018; 67:628.</a></li><li><a class="nounderline abstract_t">Qamar FN, Yousafzai MT, Sultana S, et al. A Retrospective Study of Laboratory-Based Enteric Fever Surveillance, Pakistan, 2012-2014. J Infect Dis 2018; 218:S201.</a></li><li><a class="nounderline abstract_t">Crump JA, Ram PK, Gupta SK, et al. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 2008; 136:436.</a></li><li class="breakAll">World Health Organization. Typhoid vaccines: WHO position paper. March 2018. http://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf (Accessed on April 04, 2018).</li><li><a class="nounderline abstract_t">Jackson BR, Iqbal S, Mahon B, Centers for Disease Control and Prevention (CDC). Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:305.</a></li><li><a class="nounderline abstract_t">House D, Ho VA, Diep TS, et al. Antibodies to the Vi capsule of Salmonella Typhi in the serum of typhoid patients and healthy control subjects from a typhoid endemic region. J Infect Dev Ctries 2008; 2:308.</a></li><li><a class="nounderline abstract_t">Thuluva S, Paradkar V, Matur R, et al. A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator. Hum Vaccin Immunother 2022; 18:2043103.</a></li><li><a class="nounderline abstract_t">Kumar Rai G, Saluja T, Chaudhary S, et al. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. Lancet Infect Dis 2022; 22:529.</a></li><li><a class="nounderline abstract_t">Syed KA, Saluja T, Cho H, et al. Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. Clin Infect Dis 2020; 71:S141.</a></li><li><a class="nounderline abstract_t">Shakya M, Colin-Jones R, Theiss-Nyland K, et al. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. N Engl J Med 2019; 381:2209.</a></li><li><a class="nounderline abstract_t">Patel PD, Patel P, Liang Y, et al. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. N Engl J Med 2021; 385:1104.</a></li><li><a class="nounderline abstract_t">Qadri F, Khanam F, Liu X, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet 2021; 398:675.</a></li><li><a class="nounderline abstract_t">Yousafzai MT, Karim S, Qureshi S, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob Health 2021; 9:e1154.</a></li><li><a class="nounderline abstract_t">Jin C, Gibani MM, Moore M, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet 2017; 390:2472.</a></li><li><a class="nounderline abstract_t">Mohan VK, Varanasi V, Singh A, et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis 2015; 61:393.</a></li><li><a class="nounderline abstract_t">Voysey M, Pollard AJ. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). Clin Infect Dis 2018; 67:18.</a></li><li><a class="nounderline abstract_t">Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2018; 5:CD001261.</a></li><li><a class="nounderline abstract_t">Levine MM, Ferreccio C, Black RE, et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007; 45 Suppl 1:S24.</a></li></ol></div><div id="topicVersionRevision">Topic 2712 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456854" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Typhoid fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837356" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752519" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752519" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752519" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30304505" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP): An Overview and Lessons Learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933020" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27657909" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular Surveillance Identifies Multiple Transmissions of Typhoid in West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30307935" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26974227" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A novel ciprofloxacin-resistant subclade of H58 Salmonella Typhi is associated with fluoroquinolone treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725804" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antimicrobial resistance in typhoidal and nontyphoidal salmonellae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23985342" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Trends of etiology and drug resistance in enteric fever in the last two decades in Nepal: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15272072" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Isolated high-level ciprofloxacin resistance in Salmonella enterica subsp. enterica serotype Paratyphi A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157558" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High-level ciprofloxacin resistance in Salmonella enterica serotype Typhi in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20828458" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bacteraemia with pleural effusions complicating typhoid fever caused by high-level ciprofloxacin-resistant Salmonella enterica serotype Typhi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24819257" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [Molecular epidemiology, antimicrobial resistance and characterization of extended-spectrum beta-lactamases of Salmonella enterica serotype Paratyphi B clinical isolates].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25340972" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ESBL-producing Salmonella enterica serovar Typhi in traveler returning from Guatemala to Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16978898" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437343" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Update on Extensively Drug-Resistant Salmonella Serotype Typhi Infections Among Travelers to or from Pakistan and Report of Ceftriaxone-Resistant Salmonella Serotype Typhi Infections Among Travelers to Iraq - United States, 2018-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34626469" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Circulation of Third-Generation Cephalosporin Resistant Salmonella Typhi in Mumbai, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34592414" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Emergence of ceftriaxone resistant Salmonella enterica serovar Typhi in Eastern India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33965548" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Salmonella Typhi acquires diverse plasmids from other Enterobacteriaceae to develop cephalosporin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733500" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20943875" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : First report of Salmonella enterica serotype paratyphi A azithromycin resistance leading to treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32699118" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A Race against Time: Reduced Azithromycin Susceptibility in Salmonella enterica Serovar Typhi in Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33515460" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Spontaneous Emergence of Azithromycin Resistance in Independent Lineages of Salmonella Typhi in Northern India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33593966" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tracking the Emergence of Azithromycin Resistance in Multiple Genotypes of Typhoidal Salmonella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31730615" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in Bangladesh identified through passive pediatric surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25912288" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antimicrobial resistance and management of invasive Salmonella disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27329848" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The emergence and outbreak of multidrug-resistant typhoid fever in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25392358" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genomic signature of multidrug-resistant Salmonella enterica serovar typhi isolates related to a massive outbreak in Zambia between 2010 and 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25458731" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Typhoid fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356352" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Multi-drug resistance and reduced susceptibility to ciprofloxacin among Salmonella enterica serovar Typhi isolates from the Middle East and Central Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28193398" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33258934" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961941" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25098613" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antimicrobial resistance, virulence profiles and molecular subtypes of Salmonella enterica serovars Typhi and Paratyphi A blood isolates from Kolkata, India during 2009-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35238369" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evaluation of Antimicrobial Susceptibility Profile in Salmonella Typhi and Salmonella Paratyphi A: Presenting the Current Scenario in India and Strategy for Future Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27090993" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Changing Patterns in Enteric Fever Incidence and Increasing Antibiotic Resistance of Enteric Fever Isolates in the United States, 2008-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463654" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Emergence of an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30507460" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30507460" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30629573" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30629573" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30629573" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9431387" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549283" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Short course quinolone therapy of typhoid fever in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846718" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7567290" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203854" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Randomized comparison of aztreonam and chloramphenicol in treatment of typhoid fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402381" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Quinolone arthropathy in animals versus children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Toxicity of quinolones in paediatric patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Use of Systemic and Topical Fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The Use of Systemic and Topical Fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711825" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380025" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15904505" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26809813" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329181" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment response in enteric fever in an era of increasing antimicrobial resistance: an individual patient data analysis of 2,092 participants enrolled into four randomised controlled trials in Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20014951" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Global trends in typhoid and paratyphoid Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837759" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24198224" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A large outbreak of Salmonella Paratyphi A infection among israeli travelers to Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35097222" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986000" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10093945" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138078" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843701" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145784" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073741" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10639383" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7845753" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8985527" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Therapeutic aspects of typhoidal salmonellosis in childhood: the Karachi experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178594" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comparison between azithromycin and cefixime in the treatment of typhoid fever in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17593957" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531174" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18493312" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24282626" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6361558" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19842390" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : High-dose intravenous dexamethasone in the management of diarrheal patients with enteric fever and encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3050856" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Treatment of severe typhoid fever in children with high dose dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9112919" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Comparison of three operations for typhoid perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21594718" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Predictor of mortality in children with typhoid intestinal perforation in a Tertiary Hospital in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15792765" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Is operative management effective in treatment of perforated typhoid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15469159" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Typhoid ileal perforation: surgical experience of 64 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909700" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Typhoid intestinal perforation in north central Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35238362" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Salmonella Typhi Shedding and Household Transmission by Children With Blood Culture-Confirmed Typhoid Fever in Vellore, South India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34586391" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Salmonella Typhi Stool Shedding by Patients With Enteric Fever and Asymptomatic Chronic Carriers in an Endemic Urban Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7142746" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30487167" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Persistent Infection and Long-Term Carriage of Typhoidal and Nontyphoidal Salmonellae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450268" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Blood group antigen secretion and gallstone disease in the Salmonella typhi chronic carrier state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14128664" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : DETECTION OF TYPHOID CARRIERS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4897185" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The treatment of chronic biliary salmonella carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7165819" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Persistence of the Salmonella typhi-paratyphi carrier state after gallbladder removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3286783" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of norfloxacin to treat chronic typhoid carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5908876" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Ampicillin in the treatment of chronic typhoid carriers. Report on fifteen treated cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/811715" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Treatment of chronic enteric fever with amoxicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/642172" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment of typhoid carriers with amoxicillin. Correlates of successful therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/601523" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Long-term co- trimoxazole treatment of chronic Salmonella carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/319963" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of chronic salmonella carriers. Study with 40 cases of S. typhi, 19 cases of S. paratyphi b and 28 cases of S. enteritidis strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35905082" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Antimicrobial agents for the treatment of enteric fever chronic carriage: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20278487" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Typhoid; clinical analysis of 360 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18869867" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522159" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Case Fatality Rate of Enteric Fever in Endemic Countries: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30060168" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A Retrospective Study of Laboratory-Based Enteric Fever Surveillance, Pakistan, 2012-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686194" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686194" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25811680" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19741294" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Antibodies to the Vi capsule of Salmonella Typhi in the serum of typhoid patients and healthy control subjects from a typhoid endemic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35333702" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34942090" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32725225" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31800986" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34525285" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34384540" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34297962" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28965718" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870324" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29351594" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29851031" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Vaccines for preventing typhoid fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582564" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
